Pds Biotechnology Corp Stock Net Asset
| PDSB Stock | USD 1.45 0.06 3.97% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess PDS Biotechnology's long-term financial health and intrinsic value.
PDS | Net Asset | Build AI portfolio with PDS Stock |
PDS Biotechnology Corp Company Net Asset Analysis
PDS Biotechnology's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current PDS Biotechnology Net Asset | 45.36 M |
Most of PDS Biotechnology's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PDS Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PDS Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for PDS Biotechnology is extremely important. It helps to project a fair market value of PDS Stock properly, considering its historical fundamentals such as Net Asset. Since PDS Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PDS Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PDS Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
PDS Total Assets
Total Assets |
|
Based on the recorded statements, PDS Biotechnology Corp has a Net Asset of 45.36 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
PDS Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PDS Biotechnology's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PDS Biotechnology could also be used in its relative valuation, which is a method of valuing PDS Biotechnology by comparing valuation metrics of similar companies.PDS Biotechnology is currently under evaluation in net asset category among its peers.
PDS Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in PDS Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of PDS Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PDS Biotechnology's value.| Shares | Ubs Group Ag | 2024-12-31 | 50.1 K | Bank Of New York Mellon Corp | 2025-03-31 | 29.3 K | Justinvest Llc | 2025-03-31 | 28.5 K | Bank Of America Corp | 2025-03-31 | 27 K | Susquehanna International Group, Llp | 2025-03-31 | 25.8 K | T. Rowe Price Associates, Inc. | 2025-03-31 | 24.9 K | Comprehensive Portfolio Management, Llc | 2025-03-31 | 19.7 K | Federation Des Caisses Desjardins Du Quebec | 2025-03-31 | 18.8 K | Tempus Wealth Planning, Llc | 2025-03-31 | 18.8 K | Armistice Capital, Llc | 2025-03-31 | 4.4 M | Vanguard Group Inc | 2025-03-31 | 1.5 M |
PDS Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 52.12 M | ||||
| Shares Outstanding | 45.71 M | ||||
| Shares Owned By Insiders | 3.08 % | ||||
| Shares Owned By Institutions | 18.10 % | ||||
| Number Of Shares Shorted | 2.9 M | ||||
| Price To Earning | 24.70 X | ||||
| Price To Book | 3.27 X | ||||
| EBITDA | (33.75 M) | ||||
| Net Income | (37.61 M) | ||||
| Cash And Equivalents | 52.98 M | ||||
| Cash Per Share | 1.86 X | ||||
| Total Debt | 21.83 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (35.03 M) | ||||
| Short Ratio | 4.37 X | ||||
| Earnings Per Share | (0.94) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 24 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 73.14 M | ||||
| Total Asset | 45.36 M | ||||
| Retained Earnings | (182.11 M) | ||||
| Working Capital | 27.97 M | ||||
| Current Asset | 39.11 M | ||||
| Current Liabilities | 4.54 M | ||||
| Net Asset | 45.36 M |
About PDS Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PDS Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PDS Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PDS Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BALY | Ballys Corp | |
| NVDA | NVIDIA | |
| MRVL | Marvell Technology Group |
Check out PDS Biotechnology Piotroski F Score and PDS Biotechnology Altman Z Score analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.